Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tough conditions continue for SThree as recruitment fees slump

(Sharecast News) - STEM-focused recruiter SThree has held on to its full-year guidance despite a weak first quarter with double-digit declines in fees for both contract and permanent positions. Group net fees were 15% lower year-on-year in the three months to 28 February at £78.4m, with the rate of decline unchanged from the fourth quarter, as fees in the bigger contract division (84% of net fees) shrank 15% and permanent placements fees fell 13%.

Each one of its main trading regions reported declining fees, while its top three countries of Germany, the US and Netherlands saw fees drop 13%, 9% and 18% respectively.

"As we look ahead, business leaders are continuing to navigate an evolving macro-economic backdrop which is weighing on investment decisions," said chief executive Timo Lehne.

"New business continues to be soft, however extensions remain robust across our core STEM Contract service offering, providing sector-leading visibility,"

The contractor order book by period-end was £168m, falling 7% on last year but at a reduced rate of decline from the end of last financial year. Future visibility was the equivalent of around five months' net fees, it said.

In line with its guidance in December, SThree expects to book a pre-tax profit for the year ending 30 November of £25m, compared with £67.6m last year.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.